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Regulatory Nod-like receptors (NLRs) are a subgroup of the cytosolic NLR family of
pathogen recognition receptors (PRRs). These receptors can tune the innate immune
responses triggered by the activation of other PRRs by either augmenting or attenuating
the activated pro-inflammatory signaling cascades. Nod-like receptor X1 (NLRX1) is the
only known mitochondria-associated negative regulatory NLR. NLRX1 attenuates several
inflammatory pathways and modulates cellular processes such as autophagy and
mitochondrial function following infection or injury. Using both in vitro expression and
in vivo experimental models, NLRX1 is extensively described in the context of anti-viral
signaling and host-defense against invading pathogens. More recently, NLRX1 has also
gained interest in the field of cancer and metabolism where NLRX1 functions to attenuate
overzealous inflammation in various inflammatory and autoimmune diseases. However,
the exact function of this novel receptor is still under debate and many, often
contradictory, mechanisms of action together with cellular localizations have been
proposed. Thus, a better understanding of the underlying mechanism is crucial for
future research and development of novel therapeutical approaches. Here, we
summarize the current findings on NLRX1 and discuss its role in both infectious and
inflammatory context.
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To respond to infection, innate immune cells of the host express multiple pathogen recognition
receptors (PRRs) that recognize different danger- and pathogen associated molecular patterns
(DAMPs and PAMPs) and induce the expression of key proinflammatory pathways. This array of
PRRs include the membrane-bound Toll-like receptors (TLRs) and C-type lectin receptors (CLRs)
and the cytosolic Rig-I-like helicase receptors (RLRs) and nucleotide-binding oligomerization
domain (NOD)-like receptors (NLRs). While the role of TLRs, CLRs, and RLRs in pathogen
recognition and cellular defense is relatively well defined, the function and mechanism of action of
most NLRs is less understood.
The NLR family contains 22 distinct members in humans and 34 in mice. These members can be
divided into inflammasome- and non-inflammasome forming subgroups (Franchi et al., 2009).
NLRs are composed of three domains: a leucine-rich repeat (LRR) containing C-terminal domaingy | www.frontiersin.org December 2020 | Volume 10 | Article 6098121
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domain (NACHT) necessary for oligomerization upon
activation, and a variable N-terminal effector domain to recruit
signaling adaptors. Upon activation, by interacting with
downstream factors, the N-terminal domain will mediate the
upregulation of the downstream signaling pathways, which are
involved in different cellular processes including inflammation
and apoptosis (Franchi et al., 2009). Many NLRs have clear
pathogen-recognition functions and directly recognize pathogen
derived molecules. For example, NOD1 and NOD2, the first
described NLRs, are directly involved in bacterial sensing by
recognizing bacterial peptidoglycan (Keestra-Gounder and
Tsolis, 2017). The best characterized and most studied
members of the NLR family are the inflammasome forming
NLRs such as NLRP3 (NOD-, LRR- and pyrin domain-
containing protein 3). The latter play a role in the immune
response against multiple pathogens including viruses, bacteria
and protozoan parasites (Kim and Jo, 2013; Lupfer and
Kanneganti, 2013; De Carvalho and Zamboni, 2020). While the
role of NLRs in antiviral and -bacterial signaling is relatively well
defined, their function and mechanism of action in parasitic
disease is less understood.
Certain NLRs, however, also function in processes independent
of infection. These latter receptors act as cytosolic innate sensors to
different DAMPs and induce an inflammatory response to cellular
damage or stress (Kufer and Sansonetti, 2011; Mason et al., 2012).
Furthermore, NLRs play important roles in many inflammatory
diseases and metabolic disorders where inflammation is a key
mediator of disease progression. For example, the NLRP3
inflammasome have been shown to be involved beyond
pathogen recognition in driving inflammation in different
autoimmune disorders and in tumorigenesis (Martinon et al.,
2002; Kufer and Sansonetti, 2011; Allen, 2014). There is growing
evidence, however, that some NLRs function independently of
inflammasome formation and may even negatively regulate
inflammation (Allen, 2014; Coutermarsh-Ott et al., 2016a). This
recent subgroup of negative regulatory NLRs is composed of three
members, NLRP12, NLRC3, and NLRX1. These receptors
function to attenuate diverse signaling pathways such as the
nuclear factor-kB (NF-kB) and type I interferon (IFN) signalling,
together with cellular processes such as generation of reactive
oxygen species (ROS) and autophagy (Coutermarsh-Ott et al.,
2016a). Particular attention is attributed to NLRX1, which
attenuates inflammatory pathways in multiple infectious and
autoimmune diseases. Here, we discuss the role of NLRX1 both
as a traditional PRR and as a modulator of cellular homeostasis
by recapitulating studies from its initial description until
recent findings.NLRX1 FUNCTIONS AS A PATHOGEN
RECOGNITION RECEPTOR
NLRX1, also named NOD5, NOD9, or CLR11.3, is the first and
only NLR to be targeted to the mitochondria. Like all NLRs,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2NLRX1 contains a central nucleotide binding domain (NBD)
and a C-terminal LRR domain. However, its unconventional
N-terminal domain shares no apparent homology to other
domains and contains a mitochondrial targeting sequence (MTS)
in its first 39 amino acids (Moore et al., 2008; Tattoli et al., 2008;
Arnoult et al., 2009). Initially, NLRX1 was described as a
mitochondrial outer membrane (MOM)-associated protein
(Moore et al., 2008). Subsequently, studies failed to detect
NLRX1 at the MOM, but rather in the mitochondrial matrix.
Arnoult et al. (2009) showed that the translocation of NLRX1 to the
matrix required mitochondrial inner membrane potential. Once in
the matrix, the N-terminal MTS is removed similarly to other
mitochondria targeted proteins (Arnoult et al., 2009). Supporting
its role in antiviral immunity, structural and functional analysis of
NLRX1 identified a C-terminal RNA-binding element that
interacts directly to ssRNA, dsRNA and poly I:C, but not DNA,
probably via multiple positive charges on its surface and this
binding was essential for ROS production (Hong et al., 2012).
Although providing structural insight to potential ligand binding, it
still remains unclear how binding to viral RNA (but not DNA)
could occur at the mitochondrial matrix and how this binding
would promote ROS production. Interestingly, several NLRs have
been shown to shuttle between distinct subcellular localizations
following stimulation (Coutermarsh-Ott et al., 2016a). Several
groups have indeed reported a change in NLRX1 localization
upon infection. Whereas in uninfected macrophages NLRX1
localizes both in the cytoplasm and at the mitochondria,
Rhinovirus infection promoted relocalization of NLRX1 from the
cytoplasm to the mitochondria of epithelial cells. Similarly,
infection of macrophages with the fungal pathogen, Histoplasma
capsulatum (H. capsulatum), promoted NLRX1 translocation to
phagosomes (Huang et al., 2018). Of note, translocation of NLRX1
to phagosomes could be of great interest in the study of the innate
immune response against intracellular pathogens, including
bacteria and protozoan parasites, that have developed strategies
to survive inside phagolysosomes.
NLRX1 was first described over 10 years ago, mostly in the
context of host defense to pathogens. Moore et al. (2008) propose
that NLRX1 negatively regulates mitochondrial antiviral
signalling protein (MAVS)-mediated type I IFN signaling by
directly interacting with MAVS through its LRR domain at the
MOM. By preventing interaction between dsRNA-activated
RIG-I and MAVS, NLRX1 functions as a negative regulator of
antiviral immunity and depletion of NLRX1 by siRNA resulted
in decreased ssRNA viral loads in HEK293T cells after Sendai
virus infection (Moore et al., 2008). However, subsequent studies
failed to identify a role in the regulation of MAVS-dependent
signalling, but rather showed that in the mitochondrial matrix
NLRX1 could potentiate ROS production in HEK293 cells upon
stimulation with TNFa and poly I:C, or infection with Shigella
by interacting with the ubiquinol-cytochrome c reductase core
protein II (UQCRC2), a matrix-facing protein of the complex III
of the mitochondrial electron transport chain (ETC) (Tattoli
et al., 2008; Arnoult et al., 2009). Mitochondria are major sources
of ROS that serve as a mechanism to suppress pathogen
replication via inflammation and apoptosis. Supporting its roleDecember 2020 | Volume 10 | Article 609812
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ROS production upon Chlamydial infection (Abdul-Sater et al.,
2010), poly I:C stimulation or Rhinovirus infection (Unger et al.,
2014) and could bind UQCRC2 in mouse embryonic fibroblasts
(MEFs) (Rebsamen et al., 2011). On the other hand, loss of
NLRX1 resulted in increased ROS production following
Helicobacter pylori (Philipson et al., 2015) or Listeria
monocytogenes (Zhang et al., 2019) infection of macrophages.
In addition, the use of an N-terminal HA-tagged NLRX1 in the
initial study by Moore et al. (2008) was further questioned since
the addition of an N-terminal tag prevented translocation of
NLRX1 to the mitochondria and overexpression of tagged-
NLRX1 resulted in a cytoplasmic pool of the NLRX1 protein
probably as a consequence of overwhelmed mitochondrial
import (Tattoli et al., 2008; Arnoult et al., 2009; Ling et al., 2012).
Following the first description by Moore et al. (2008) and
Tattoli et al. (2008), four independent groups generated mice
models to further investigate the role of NLRX1 in infection
(Table 1). Allen et al. (2011) generated a knock out (KO) mouse
model by deleting the exon 4 and 5 of NLRX1 corresponding to its
nucleotide binding domain (NBD). NLRX1 KO mice challenged
with LPS or infected with Influenza virus showed higher
inflammation and type I IFN signaling. NLRX1 attenuated
MAVS-dependent RIG-I signalling in MEFs after stimulation
with poly I:C, but not in bone marrow derived macrophages
(BMDMs). Although it is possible that NLRX1 function is cell type
specific, differences in inflammatory response between the two cell
types may be due to a more potent activation of NF-kB and IRF3
pathways in MEFs compared to BMDMs (Li et al., 2019). In
contrast, NLRX1 attenuated NF-kB signalling in both LPS or
TNFa treated MEFs and BMDMs by interacting with TRAF6
ubiquitin ligase (Allen et al., 2011). Xia et al. (2011) generated a
shRNA knockdown (KD) mouse model whereby mice were
shown to be more susceptible to LPS-induced septic shock, but
not to poly I:C treatment. In contrast, in vitro KD macrophages
showed increased IL-6 and TNFa production after stimulation
with several TLR ligands, including LPS, poly I:C and CpG DNA
(Xia et al., 2011). Similarly to Allen et al. (2011); Xia et al. (2011)
showed that NLRX1 inhibits TLR-induced NF-kB signalling by
binding through its LRR domain to TRAF6 in unstimulated cells
and the IKK complex upon LPS stimulation (Xia et al., 2011). Both
studies used luciferase reporter assays and HA-taggedFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3overexpression models to investigate the mechanism of
regulation of NF-kB and type I IFN pathways. These methods
were subsequently described as unreliable as activation of the
luciferase reporter was shown to be a non-specific effect of the
overexpression of the LRR domain (Ling et al., 2012; Soares et al.,
2013). In agreement, Rebsamen et al. (2011) generated a third
mouse model by deleting exons 1 to 4 and showed that NLRX1 did
not affect MAVS-dependent antiviral signalling following
intravenous injection of poly I:C or cytokine production in
MEFs, or BMDMs, following poly I:C treatment or Sendai virus
infection, respectively (Rebsamen et al., 2011). Similar
observations were described by Soares et al. (2013) using a
fourth KO mouse model having a deletion of exon 3 after
intranasal challenge with Influenza A virus or intraperitoneal
injection of poly I:C. NLRX1 did not affect IL-6 production or
type I IFN expression neither in BMDMs, nor MEFs, infected with
Sendai virus.
In the field of innate immunity, NLRX1 has still gained a lot of
attention in recent years. Several mechanisms of action have been
proposed, with many contradicting previous observations. Feng
et al. (2017) proposed an interesting model, where NLRX1
negatively regulated the MAVS-mediated anti-viral IRF3
pathway, but promoted early IRF1-mediated anti-viral signaling
by competitively binding dsRNA and thus preventing translational
shutdown of IRF1 mediated by the dsRNA-activated protein
kinase PKR. Thus, the effect of NLRX1 would depend on
whether the host response is driven by IRF1 or IRF3. The
mechanism of action of NLRX1 has been also shown to be cell-
specific. In a model of invasive pulmonary aspergillosis (IPA),
Kastelberg et al. (2020) showed that loss of NLRX1 in CD103+
dendritic cells resulted in higher mortality in mice due to an
increased IL-4 production via enhanced c-Jun N-terminal kinase
(JNK) pathway. On the contrary, the loss of NLRX1 in non-
hematopoietic cells resulted in increased IL-6 and CXCL8/IL-8
production via elevated p38 activation and was associated with
increased innate immune cell recruitment and survival in vivo
(Kastelberg et al., 2020). Many factors have also been shown to
compete with NLRX1. For example, FAS-associated factor-1
(FAF1) promoted anti-viral signaling and the type I IFN
response by targeting NLRX1 and preventing its binding to
MAVS (Kim et al., 2017). Another study showed that NLRX1
induced the degradation of MAVS through recruitment andTABLE 1 | Mouse models to study NLRX1.
Author, Year Knock out
model
Effect of NLRX1
Allen et al. (2011) Deletion of exon 4
and 5
Inhibitory effect on MAVS-signaling: NLRX1 KO mice showed increased inflammation and type I IFN signaling after LPS
challenge of Influenza virus (ssRNA) infection
Xia et al. (2011) shRNA
knockdown
Inhibitory effect on NF-KB signaling: NLRX1 KD mice were more susceptible to LPS-induced septic shock, but not to poly
I:C treatment
Rebsamen et al. (2011) Deletion of exon 1
to 4
No effect on MAVS signaling: no difference between WT and KO mice after Sendai virus (ssRNA) infection or i.v injection
of poly I:C
Soares et al. (2013) Deletion of exon 3 No effect on MAVS signaling: no difference between WT and KO mice after intranasal challenge with Influenza A virus
(ssRNA) or i.p injection of poly I:CIFN, interferon; i.v, intra-venous; KD, knockdown; KO, knock-out; LPS, lipopolysaccharide; MAVS, mitochondrial anti-viral signaling protein; NF-KB, nuclear factor kappa-light-chain-
enhancer of activated B cells; WT, wild type.December 2020 | Volume 10 | Article 609812
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hepatitis C virus infection (Qin et al., 2017). In addition, NLRX1
inhibited type I IFN signaling also in response to DNA viruses and
promoted viral replication by sequestering the cytosolic DNA
sensor STING (Guo et al., 2016), or to herpesviruses by inhibiting
MAVS-signaling (Ma et al., 2017). On the other hand, NLRX1
restricted virus replication by interacting with a viral non-
structural protein 9 (Nsp9) RNA-dependent RNA polymerase
domain of PRRSV2 virus (porcine reproductive and respiratory
syndrome virus-2) (Jing et al., 2019). Taken together, a consensus
regarding ligand specificity, stimuli-specific subcellular
localization and mechanism of action is yet to be further defined.NLRX1 ATTENUATES TUMORIGENESIS
AND INFLAMMATION
NLRX1 was also shown to attenuate inflammation and regulate
cellular homeostasis independently of its role in pathogen
recognition. The loss of NLRX1 is associated with more severe
inflammation and tissue damage in different models of
inflammation such as cancer. In SV40 transformed MEFs, but
not in primary cells, NLRX1 mediated resistance to
mitochondria dependent extrinsic apoptosis induced by TNFa-
cycloheximide (CHX), but susceptibility to intrinsic apoptosis
caused by glucose starvation or endoplasmic reticulum
(ER) stress (Soares et al., 2014). Coherently, NLRX1 KO
mice had fewer tumors in an azoxymethane induced colorectal
cancer model probably due to a lower rate of intrinsic
apoptosis, however, there was increased pathology in a dextran
sodium sulfate (DSS)/azoxymethane colitis model in which
accumulation of inflammatory mediators such as TNFa trigger
excessive extrinsic apoptosis (Soares et al., 2014). Further studies
confirmed the role of NLRX1 in tumorigenesis. Singh et al.
(2015) showed that NLRX1 suppressed tumorigenicity and
migration in human breast cancer cell lines by promoting
TNFa-induced mtROS production and caspase-8 mediated
apoptosis (Singh et al., 2015). Similarly, in a model of
urethane-induced histiocytic sarcoma, NLRX1 attenuated
cancer progression by negative regulation of pro-survival NF-
kB and AKT signalling pathways in BMDMs (Coutermarsh-Ott
et al., 2016b). Additional mouse models including Cre-mice
lacking NLRX1 in intestinal epithelial cells (Tattoli et al.,
2016), or bone marrow chimeras lacking NLRX1 in non-
hematopoietic cells (Koblansky et al., 2016) confirmed the role
of NLRX1 as a tumor suppressor in intestinal epithelial cells.
Interestingly, NLRX1 expression was decreased only in cancer
cell lines with high metastasis potential and NLRX1 was shown
to promote apoptosis (Kang et al., 2015) and senescence in tumor
cells while repressing invasiveness by inhibition of AKT pathway
(Hu et al., 2018; Singh et al., 2019).
Although NLRX1 was first described to attenuate inflammation
in transformed cells, loss of NLRX1 is also linked to more severe
inflammation in different models of tissue injury. The effect of
NLRX1 has been studied extensively in the context of central
nervous system (CNS) inflammation. In the brain, NLRX1Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4attenuated macrophage-induced inflammation in mice in a
model of experimental encephalomyelitis (Eitas et al., 2014), and
the NF-kB responsive genes in a model of traumatic brain injury
(Theus et al., 2017). Gharagozloo et al. (2019) later further
confirmed the observations of Eitas et al. (2014) and showed that
NLRX1 prevented CNS inflammation, immune cell infiltration and
the generation of neurotoxic astrocytes in a model of spontaneous
experimental autoimmune encephalomyelitis (Gharagozloo et al.,
2019). In addition, the LRR domain of NLRX1 could alleviate
autoimmune encephalomyelitis when delivered to the brain by
reducing tissue inflammation, CD45+ immune cell and CD4+
IFNy+ T cell infiltration (Koo et al., 2020). Similarly to Allen et al.
(2011) and Xia et al. (2011); Peng et al. (2020) propose in a model
of cerebral ischemia/reperfusion injury that DJ-1 (PARK7), a
potential antioxidant mitochondrial protein, promoted NLRX1
dissociation from TRAF6 to negatively regulate NF-kB signalling
(Peng et al., 2020). In other tissues, NLRX1 has been shown to
regulate inflammation in a similar manner. Ma et al. (2019) showed
that NLRX1 attenuated LPS-induced inflammation and apoptosis
in chondrocytes by negative regulation of NF-kB signalling in a
model of osteoarthritis (Ma et al., 2019). How NLRX1 regulates
NF-kB signalling remains unclear. Similarly toMAVS, the targeting
of cytosolic TRAF6 raises again the question of the localization of
NLRX1. In addition to a potential, maybe minor, cytoplasmic pool
of NLRX1, it is possible that TRAF6 translocates to the
mitochondria upon stimulation. Interestingly, West et al. (2011)
showed that stimulation of cell surface-bound TLRs such as TLR4
and TLR1/2 of RAW macrophages resulted in the translocation of
TRAF6 at the mitochondria, but it was not the case after
stimulation with TLR3 agonist, poly I:C. Thus, the effect of
NLRX1 on NF-kB signalling may highly be dependent on the
upstream TLR stimulation.
On the other hand, protection against inflammation has also
been linked to MAVS-dependent signaling. NLRX1 protected
against inflammation in mice in a smoke-induced chronic
obstructive pulmonary disease model by inhibiting MAVS-
RIG-I pathway, or by inhibiting MAVS-dependent NLPR3
inflammasome activation in hypoxia-induced cardiomyocytes
in two different models of myocardial injury (Li et al., 2016;
Tong et al., 2020). Although most often linked to increased
inflammation and lesion severity, the loss of NLRX1 also
promoted healing by enhancing angiogenesis through miR-195
upregulation (Liu et al., 2018), or by increased expression of
wound healing factors such as epidermal growth factor (EGF)
and transforming growth factor beta 1 (TGFb1) following injury
(Tattoli et al., 2016).NLRX1 REGULATES MITOCHONDRIAL
FUNCTION AND METABOLISM
Unlike other NLRs, NLRX1 localizes at the mitochondria, the
central hub for both metabolism and immunity. Recent studies
suggest that NLRX1, instead of being a traditional PRR, may in
fact play a more general role in the maintenance of mitochondrial
physiology and function. In NLRX1 knock-in (KI) neuroblastomaDecember 2020 | Volume 10 | Article 609812
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(DRP1), a major regulator of mitochondrial dynamics, resulted in
increased mitochondrial fission, and the mitochondria in these
cells showed morphological abnormalities (Imbeault et al., 2014).
Similar observations were described in auditory cells in which
overexpression of NLRX1 resulted in mitochondrial swelling and
breakage of the cristae (Yin et al., 2018). On the other hand, loss of
NLRX1 resulted in decreased mitochondrial membrane potential
and in increased caspase-3 mediated mitochondrial apoptosis in
virus infected BMDMs (Jaworska et al., 2014). However, the
protective effect of NLRX1 was mediated by interaction with a
viral protein PB1-F2 of Influenza A virus, thus not providing
evidence of a more general mechanism of action.
The activity of mitochondrial respiratory chain complexes is
important for the regulation of ATP levels within the cell. In
addition to ATP, the mitochondrial respiratory chain is also a
major source of mitochondrial ROS (mtROS). NLRX1 regulates
mtROS by modulating the two major sites of mtROS production,
the complex I and complex III of the ETC. NLRX1 protected
against mitochondrial damage and oxidative stress in kidney
epithelial cells and loss of NLRX1 resulted in increased
mitochondrial fragmentation, oxidative phosphorylation
(OXPHOS), and complex II/III activity (Stokman et al., 2017).
Mechanistically, NLRX1 locates at the mitochondrial matrix where
it associates with the Fas-activated serine-threonine kinase family
protein-5 (FASTKD5), a component of mitochondrial RNA
granules. This association was shown to negatively regulate RNA
processing of mitochondrial complex units (Singh et al., 2018).
Interestingly, NLRX1 protected against mitochondrial injury in
both infection (Zhang et al., 2019), and in in vitromodels of injury
by sodium azide or glucose starvation (Chu et al., 2019).
Mitochondrial injury leads to increased inflammation, and thus
NLRX1 may negatively regulate inflammation by direct
maintenance of mitochondrial homeostasis.
Mitochondria emerge as key players in maintenance of
homeostasis and in host innate defense mechanisms. Any
metabolic stress or infectious agents that alter the function or
damage mitochondria will lead to the fragmentation and
subsequent degradation of defective and/or depolarized
mitochondria by mitophagy or by apoptosis (Toyama et al.,
2016). Impaired removal of damaged mitochondria leads to the
release of multiple DAMPs to the cytosol, or to the extracellular
space which triggers innate immune responses and inflammation
(Banoth and Cassel, 2018; Harris et al., 2018). Intriguingly, NLRX1
could regulate autophagy and/or mitophagy in infectious diseases
and in models of cell stress. Autophagy is a highly conserved
process requiring mitochondrial function to recycle and degrade
proteins within an autophagosome-lysosome fusion mainly upon
cellular stress such as starvation (Shibutani et al., 2015; Singh
et al., 2019). Autophagy is also induced by many pathogens
including bacteria, viruses and parasites and is a potent host
defense mechanism. In addition, autophagy has been shown to
suppress inflammasome activation, to negatively regulate RLR-
mediated type I IFN production and to promote MHC class II
antigen presentation (Shibutani et al., 2015). Some pathogens,
including bacteria and viruses, can impact mitochondrial
metabolism, usually by inhibiting mitochondrial OXPHOS toFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 5favor their intracellular survival. On the contrary, the metabolic
modifications can promote the immune response (Tiku et al.,
2020). Mitochondrial dynamics and mitophagy are important
mechanisms to regulate innate immune response to infection
and can mediate macrophage activation towards a pro-
inflammatory phenotype and microbial clearance (Gkikas
et al., 2018).
Lei et al. (2012) showed that NLRX1 inhibited type I IFN
production in MEFs by associating with mitochondrial matrix
protein Tu translation elongation factor (TUFM) via its
N-terminus. TUFM interacts with the autophagy-related
proteins Atg5-Atg12 and promotes autophagy during vesicular
stomatitis viral infection. The same group showed TUFM-
NLRX1 interaction also in cancer cells, in which NLRX1
promoted cetuximab, an epidermal growth factor receptor
(EGFR) inhibitor, -induced autophagy and mediated resistance
to cancer treatment (Lei et al., 2016). Interestingly, cetuximab
has been shown to enhance ER-Stress- and mitochondria-
mediated apoptosis through ROS production (Kang et al.,
2020). Interaction with TUFM was further confirmed in
macrophages infected with a fungal pathogen, H. capsulatum.
NLRX1-TUFM promoted LC3-associated phagocytosis (LAP) of
H. capsulatum and LAP-mediated cytokine production via
MAPK-AP-1 pathway (Huang et al., 2018). Some pathogens
have evolved to escape from autophagy-mediated killing or even
use the autophagy machinery as part of their replication cycle. A
bacterial pathogen, Listeria monocytogenes (L. monocytogenes)
was shown to induce NLRX1-dependent mitophagy to avoid
killing (Zhang et al., 2019). Mechanistically, for the first time,
Zhang et al. (2019) showed that NLRX1 contains a LC3-
interacting domain (LIR), and its direct interaction with LC3
induced L. monocytogenes-dependent mitophagy and suppressed
mtROS production. Similarly, the human papilloma virus 16
(HPV16) has developed a mechanism to suppress the STING-
mediated DNA sensing pathway in an autophagy-dependent
manner. Luo et al. (2020) showed that the E7 protein of
HPV16 could bind NLRX1 and promoted autophagy-
dependent degradation of STING leading to decreased anti-
viral type I IFN production (Luo et al., 2020). On the other
hand, NLRX1 inhibited bacterial invasion and the consequent
autophagosome formation and maturation following
Streptococcus A infection in HeLa cancer cells by interacting
with the Beclin-1-UVRAG complex via the NACHT domain,
similarly to other NLRs such as NLRC4 and NLRP4 (Aikawa
et al., 2018). Likewise, in other cancer cell lines, NLRX1
suppressed TNFa induced autophagy and mitophagy (Singh
et al., 2019), potentially indicating that the effect of NLRX1 on
autophagy might differ between transformed and primary
cell lines.
With the expansion of the immunometabolism field, growing
interest has been attributed to the role of NLRX1 as a modulator
between inflammation and metabolism. The first observations
that NLRX1 could directly regulate metabolism were made in
cancer cells. These cells are highly glycolytic and inhibition of
glycolysis was shown to result in decreased NLRX1 expression in
both primary and transformed MEFs (Soares et al., 2014).
Similarly, in other cancer cell lines, NLRX1 downregulated theDecember 2020 | Volume 10 | Article 609812
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the metabolic switch towards aerobic glycolysis (Singh et al.,
2015; Singh et al., 2019). The effect on metabolism is likely to be
cell type and microenvironment dependent. Indeed, in CD4+ T
cells, NLRX1 was shown to promote mitochondrial oxidative
metabolism and NLRX1 KO mice had increased populations of
both Th1 and Th17 inflammatory cells. In addition to glucose
metabolism, NLRX1 regulated fatty acid metabolism. Under a
high fat diet, NLRX1 KO mice had increased fatty acid-
dependent OXPHOS and were protected from diet-induced
hepatic steatosis (Kors et al., 2018) and pancreatic lipid
accumulation (Costford et al., 2018). Interestingly, different
lipids such as coenzyme A-containing fatty acids and sterols
were shown to bind the LRR domain of NLRX1 and punicic acid
(PUA), a polyunsaturated fatty acid, exerted anti-inflammatory
effects in a NLRX1-dependent manner in LPS-activated BMDMs
or in a DSS-induced colitis mice model (Lu et al., 2015).
In addition, NLRX1 regulated glutamine metabolism as
NLRX1 KO mice showed increased glutamine utilization and
interestingly glutamine supplementation alleviated the severityFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 6of inflammatory bowel disease in mice (Leber et al., 2018).
Altogether, NLRX1 is a promising therapeutic target as an
immunometabolic regulator of inflammation. As a proof of
principle, Leber et al., 2019a developed a small molecule,
NX-13, that showed anti-inflammatory effects by activating
NLRX1 of a small molecule in an in vivo model of inflammatory
bowel disease (Leber et al., 2019a; Leber et al., 2019b).DISCUSSION
NLRX1 is the only known mitochondria-associated innate
immune receptor of the NLR family and it has now become
evident that its role extends from traditional pathogen
recognition to the regulation of different cellular functions to
control inflammation (Figure 1). However, as highlighted by the
diverse effects of NLRX1 that have been described, the exact
mechanism through which NLRX1 influences inflammation, the
immune response or metabolism is still under debate (Figure 2).
Many open questions remain regarding ligand specificity,FIGURE 1 | NLRX1 regulates multiple cellular pathways to control inflammation in response to infection and stress. NLRX1 is addressed to the mitochondria via the
N-terminal mitochondrial targeting sequence (MTS). Studies identified a C-terminal RNA-binding element and coherently, NLRX1 plays a role in anti-viral signaling by
inhibition of type I interferon signaling through direct interaction with the outer membrane (OM) mitochondrial anti-viral signaling protein (MAVS). However, some
studies describe that NLRX1 attenuates viral replication in the cytoplasm via a MAVS-independent mechanism, potentially through binding of stimulator of interferon
genes (STING). Inhibition of type I IFN signalling following virus infection is associated to enhanced autophagy and mitophagy through association of NLRX1 with
either the Tu translation elongation factor (TUFM) or GTPase dynamin-related protein 1 (DRP1). Similarly, NLRX1 is associated to enhanced mitochondrial reactive
oxygen species (mtROS) production and decreased oxygen consumption and mitochondrial oxidative phosphorylation (OXPHOS) following virus or bacterial infection
through interaction with the mitochondrial protein ubiquinol-cytochrome c reductase core protein II (UQCRC2). Growing interest has been attributed to the role of
NLRX1 as a modulator between inflammation and metabolism. Following cellular stress, NLRX1 inhibits activation of NF-kB through its direct interaction with TRAF6
or IkB kinase (IKK) complex. NLRX1 may indeed play a more general role in the maintenance of mitochondrial physiology and cellular homeostasis. AP-1, activator
protein 1; cGAS, cyclic GMP-AMP synthase; ER, endoplasmic reticulum; FASTKD5, FAST kinase domain-containing protein 5; IKKa, IkB kinase subunit a; IKKb, IkB
kinase subunit b; IM, inner membrane; IRF3, interferon regulatory factor 3; JNK, c-Jun N-terminal kinase; LC3, microtubule-associated protein 1A/1B-light chain 3;
LIR, LC3-interacting domain; LRR, leucine rich repeat domain; MAPK, mitogen-activated protein kinase; NACHT, central nucleotide-binding oligomerization domain;
NEMO, NF-kB essential modulator; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; p38, p38 mitogen activated protein kinase; RIG-I, retinoic
acid-inducible gene I; TAK1, transforming growth factor-b activated kinase-1; TBK1, TANK-binding kinase 1; TRAF6, TNF receptor-associated factor 6.December 2020 | Volume 10 | Article 609812
Snäkä and Fasel NLRX1 in Infection and Inflammationcellular localization and mechanisms of action. How NLRX1
would bind viral RNA from the mitochondria remains unclear.
Similarly, more evidence is required to explain the interaction
with cytosolic proteins such as TRAF6 or STING, or
mitochondrial outer membrane proteins such as MAVS. It is
possible that the function of NLRX1 is highly dependent on the
cellular environment and an altered metabolic state could
explain some of the differences observed in the differentFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 7infectious and cancer models. Interestingly, NLRX1 has been
shown to regulate autophagy, a cellular process mediated by
mitochondrial function, the metabolic state of the cell and ROS
production, both in infected and cancer cells and could thus
provide a more general mechanism of action. Indeed, autophagy
plays an important role in the immune response against
intracellular pathogens as well as in the maintenance of cellular
homeostasis, but it can also be used as an immune evasionFIGURE 2 | NLRX1 modulates innate immunity and inflammation. Multiple mechanisms of action and direct interacting partners are proposed in different
experimental models. The N-terminal central nucleotide-binding domain (NACHT) of NLRX1 plays a role in attenuating MAVS-dependent anti-viral signalling by
inhibiting the type I interferon (IFN) response against both ssRNA and dsRNA viruses. In addition, the NACHT domain was necessary to inhibit invasion and
autophagosome formation upon Streptococcus A infection. Multiple functions are proposed to depend on the C-terminal leucine rich repeat (LRR). LRR was shown
to directly bind a viral RNA polymerase Nsp9 of porcine reproductive and respiratory syndrome virus-2 (PRRSV2) to limit virus replication, or to bind LC3 to induce
Listeria monocytogenes-dependent mitophagy, or to induce mtROS upon RNA stimulation. The LRR also limited inflammation in both infectious and inflammatory
disease models. Many binding partners have been proposed using the endogenous protein. NLRX1 could play a role in modulating type I IFN signalling, NF-KB
pathway, autophagy and several mitochondrial functions. Thus, a consensus regarding the exact mechanism of action of NLRX1 still requires further investigation.
DRP1, GTPase dynamin-related protein 1; FASTKD5, FAST kinase domain-containing protein 5; HPV, human papillomavirus; IKK, IkB kinase; LC3, microtubule-
associated protein 1A/1B-light chain 3; LPS, lipopolysaccharide; MTS, mitochondrial targeting sequence; MAVS, mitochondrial anti-viral signaling protein; NF-kB,
nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3, NOD-, LRR- and pyrin domain-containing protein 3; Nsp9, a viral non-structural protein 9;
PB1-F2, influenza virus protein PB1-F2; PCBC2, poly(rC) binding protein 2; ROS, reactive oxygen species; STING, stimulator of interferon genes; TBK1, TANK-
binding kinase 1; TRAF6, TNF receptor-associated factor 6, TUFM, Tu translation elongation factor; UQCRC2, ubiquinol-cytochrome c reductase core protein II;
UVRAG, UV irradiation resistance-associated gene.December 2020 | Volume 10 | Article 609812
Snäkä and Fasel NLRX1 in Infection and Inflammationstrategy by pathogens that replicate within the phagolysosome.
However, whether NLRX1 directly regulates inflammation via
autophagy still requires further investigation. Taken together, as
a mitochondrial protein, NLRX1 provides a direct link between
innate immunity, metabolism and mitochondrial control of
inflammation. Additional studies are required to further
characterize this peculiar NLR, however it seems that NLRX1
may represent an interesting target as a regulator of both innate
immunity and cellular physiology.AUTHOR CONTRIBUTIONS
TS contributed to the literature search and wrote the first draft of
the manuscript. TS and NF contributed to manuscript revisionFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 8and discussion. All authors contributed to the article and
approved the submitted version.FUNDING
This work was supported by the Swiss National Fund for
Research (FNRS No. 310030_173180 and IZRJZ3_164176/1).ACKNOWLEDGMENTS
We thank Slavica Masina for critical reading of the manuscript
and Adrien Fasel for polishing Figure 1.REFERENCES
Abdul-Sater, A. A., Said-Sadier, N., Lam, V.M., Singh, B., Pettengill, M. A., Soares, F.,
et al. (2010). Enhancement of reactive oxygen species production and chlamydial
infection by the mitochondrial Nod-like family member NLRX1. J. Biol. Chem.
285, 41637–41645. doi: 10.1074/jbc.M110.137885
Aikawa, C., Nakajima, S., Karimine, M., Nozawa, T., Minowa-Nozawa, A., Toh, H.,
et al. (2018). NLRX1 Negatively Regulates Group A Streptococcus Invasion and
Autophagy Induction by InteractingWith the Beclin 1-UVRAGComplex. Front.
Cell Infect. Microbiol. 8, 403. doi: 10.3389/fcimb.2018.00403
Allen, I. C., Moore, C. B., Schneider, M., Lei, Y., Davis, B. K., Scull, M. A., et al.
(2011). NLRX1 protein attenuates inflammatory responses to infection by
interfering with the RIG-I-MAVS and TRAF6-NF-kappaB signaling pathways.
Immunity 34, 854–865. doi: 10.1016/j.immuni.2011.03.026
Allen, I. C. (2014). Non-Inflammasome Forming NLRs in Inflammation and
Tumorigenesis. Front. Immunol. 5, 169. doi: 10.3389/fimmu.2014.00169
Arnoult, D., Soares, F., Tattoli, I., Castanier, C., Philpott, D. J., and Girardin, S. E.
(2009). An N-terminal addressing sequence targets NLRX1 to the
mitochondrial matrix. J. Cell Sci. 122, 3161–3168. doi: 10.1242/jcs.051193
Banoth, B., and Cassel, S. L. (2018). Mitochondria in innate immune signaling.
Transl. Res. 202, 52–68. doi: 10.1016/j.trsl.2018.07.014
Chu, X., Wu, S., and Raju, R. (2019). NLRX1 Regulation Following Acute
Mitochondrial Injury. Front. Immunol. 10, 2431. doi: 10.3389/
fimmu.2019.02431
Costford, S. R., Tattoli, I., Duan, F. T., Volchuk, A., Klip, A., Philpott, D. J., et al.
(2018). Male Mice Lacking NLRX1 Are Partially Protected From High-Fat
Diet-Induced Hyperglycemia. J. Endocr. Soc. 2, 336–347. doi: 10.1210/js.2017-
00360
Coutermarsh-Ott, S., Allen, I. C., and Eden, K. (2016a). Beyond the
inflammasome: regulatory NOD-like receptor modulation of the host
immune response following virus exposure. J. Gen. Virol. 97, 825–838. doi:
10.1099/jgv.0.000401
Coutermarsh-Ott, S., Simmons, A., Capria, V., Leroith, T., Wilson, J. E., Heid, B.,
et al. (2016b). NLRX1 suppresses tumorigenesis and attenuates histiocytic
sarcoma through the negative regulation of NF-kappaB signaling. Oncotarget 7,
33096–33110. doi: 10.18632/oncotarget.8861
De Carvalho, R. V. H., and Zamboni, D. S. (2020). Inflammasome Activation in
Response to Intracellular Protozoan Parasites. Trends Parasitol. 36, 459–472.
doi: 10.1016/j.pt.2020.02.006
Eitas, T. K., Chou, W. C., Wen, H., Gris, D., Robbins, G. R., Brickey, J., et al. (2014).
The nucleotide-binding leucine-rich repeat (NLR) family member NLRX1
mediates protection against experimental autoimmune encephalomyelitis and
represses macrophage/microglia-induced inflammation. J. Biol. Chem. 289,
4173–4179. doi: 10.1074/jbc.M113.533034
Feng, H., Lenarcic, E. M., Yamane, D., Wauthier, E., Mo, J., Guo, H., et al. (2017).
NLRX1 promotes immediate IRF1-directed antiviral responses by limiting
dsRNA-activated translational inhibition mediated by PKR. Nat. Immunol 18,
1299–1309. doi: 10.1038/ni.3853Franchi, L., Warner, N., Viani, K., and Nunez, G. (2009). Function of Nod-like
receptors in microbial recognition and host defense. Immunol. Rev. 227, 106–
128. doi: 10.1111/j.1600-065X.2008.00734.x
Gharagozloo, M., Mahmoud, S., Simard, C., Yamamoto, K., Bobbala, D.,
Ilangumaran, S., et al. (2019). NLRX1 inhibits the early stages of CNS
inflammation and prevents the onset of spontaneous autoimmunity. PloS
Biol. 17, e3000451. doi: 10.1371/journal.pbio.3000451
Gkikas, I., Palikaras, K., and Tavernarakis, N. (2018). The Role of Mitophagy in
Innate Immunity. Front. Immunol. 9, 1283. doi: 10.3389/fimmu.2018.01283
Guo, H., Konig, R., Deng, M., Riess, M., Mo, J., Zhang, L., et al. (2016). NLRX1
Sequesters STING to Negatively Regulate the Interferon Response, Thereby
Facilitating the Replication of HIV-1 and DNA Viruses. Cell Host Microbe 19,
515–528. doi: 10.1016/j.chom.2016.03.001
Harris, J., Deen, N., Zamani, S., and Hasnat, M. A. (2018). Mitophagy and the
release of inflammatory cytokines. Mitochondrion 41, 2–8. doi: 10.1016/
j.mito.2017.10.009
Hong, M., Yoon, S. I., and Wilson, I. A. (2012). Structure and functional
characterization of the RNA-binding element of the NLRX1 innate immune
modulator. Immunity 36, 337–347. doi: 10.1016/j.immuni.2011.12.018
Hu, B., Ding, G. Y., Fu, P. Y., Zhu, X. D., Ji, Y., Shi, G. M., et al. (2018). NOD-like
receptor X1 functions as a tumor suppressor by inhibiting epithelial-
mesenchymal transition and inducing aging in hepatocellular carcinoma
cells. J. Hematol. Oncol. 11, 28. doi: 10.1186/s13045-018-0573-9
Huang, J. H., Liu, C. Y., Wu, S. Y., Chen, W. Y., Chang, T. H., Kan, H. W., et al.
(2018). NLRX1 Facilitates Histoplasma capsulatum-Induced LC3-Associated
Phagocytosis for Cytokine Production in Macrophages. Front. Immunol. 9,
2761. doi: 10.3389/fimmu.2018.02761
Imbeault, E., Mahvelati, T. M., Braun, R., Gris, P., and Gris, D. (2014). Nlrx1
regulates neuronal cell death.Mol. Brain 7, 90. doi: 10.1186/s13041-014-0090-x
Jaworska, J., Coulombe, F., Downey, J., Tzelepis, F., Shalaby, K., Tattoli, I., et al.
(2014). NLRX1 prevents mitochondrial induced apoptosis and enhances
macrophage antiviral immunity by interacting with influenza virus PB1-F2
protein. Proc. Natl. Acad. Sci. U.S.A. 111, E2110–E2119. doi: 10.1073/
pnas.1322118111
Jing, H., Song, T., Cao, S., Sun, Y., Wang, J., Dong, W., et al. (2019). Nucleotide-
binding oligomerization domain-like receptor X1 restricts porcine
reproductive and respiratory syndrome virus-2 replication by interacting
with viral Nsp9. Virus Res. 268, 18–26. doi: 10.1016/j.virusres.2019.05.011
Kang, M. J., Yoon, C. M., Kim, B. H., Lee, C. M., Zhou, Y., Sauler, M., et al. (2015).
Suppression of NLRX1 in chronic obstructive pulmonary disease. J. Clin.
Invest. 125, 2458–2462. doi: 10.1172/JCI71747
Kang, N., Cao, S., Jiang, B., Zhang, Q., Donkor, P. O., Zhu, Y., et al. (2020).
Cetuximab enhances oridonin-induced apoptosis through mitochondrial
pathway and endoplasmic reticulum stress in laryngeal squamous cell
carcinoma cells. Toxicol. In Vitro 67, 104885. doi: 10.1016/j.tiv.2020.104885
Kastelberg, B., Tubau-Juni, N., Ayubi, T., Leung, A., Leber, A., Hontecillas, R., et al.
(2020). NLRX1 is a key regulator of immune signaling during invasive pulmonary
aspergillosis. PloS Pathog. 16, e1008854. doi: 10.1371/journal.ppat.1008854December 2020 | Volume 10 | Article 609812
Snäkä and Fasel NLRX1 in Infection and InflammationKeestra-Gounder, A. M., and Tsolis, R. M. (2017). NOD1 and NOD2: Beyond
Peptidoglycan Sensing. Trends Immunol. 38, 758–767. doi: 10.1016/
j.it.2017.07.004
Kim, J. H., Park, M. E., Nikapitiya, C., Kim, T. H., Uddin, M. B., Lee, H. C., et al.
(2017). FAS-associated factor-1 positively regulates type I interferon response
to RNA virus infection by targeting NLRX1. PloS Pathog. 13, e1006398. doi:
10.1371/journal.ppat.1006398
Kim, J. J., and Jo, E. K. (2013). NLRP3 inflammasome and host protection against
bacterial infection. J. Korean Med. Sci. 28, 1415–1423. doi: 10.3346/
jkms.2013.28.10.1415
Koblansky, A. A., Truax, A. D., Liu, R., Montgomery, S. A., Ding, S., Wilson, J. E.,
et al. (2016). The Innate Immune Receptor NLRX1 Functions as a Tumor
Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting
Signals. Cell Rep. 14, 2562–2575. doi: 10.1016/j.celrep.2016.02.064
Koo, J. H., Kim, D. H., Cha, D., Kang, M. J., and Choi, J. M. (2020). LRR domain of
NLRX1 protein delivery by dNP2 inhibits T cell functions and alleviates
autoimmune encephalomyelitis. Theranostics 10, 3138–3150. doi: 10.7150/
thno.43441
Kors, L., Rampanelli, E., Stokman, G., Butter, L. M., Held, N. M., Claessen, N., et al.
(2018). Deletion of NLRX1 increases fatty acid metabolism and prevents diet-
induced hepatic steatosis and metabolic syndrome. Biochim. Biophys. Acta
Mol. Basis Dis. 1864, 1883–1895. doi: 10.1016/j.bbadis.2018.03.003
Kufer, T. A., and Sansonetti, P. J. (2011). NLR functions beyond pathogen
recognition. Nat. Immunol. 12, 121–128. doi: 10.1038/ni.1985
Leber, A., Hontecillas, R., Tubau-Juni, N., Zoccoli-Rodriguez, V., Abedi, V., and
Bassaganya-Riera, J. (2018). NLRX1 Modulates Immunometabolic
Mechanisms Controlling the Host-Gut Microbiota Interactions during
Inflammatory Bowel Disease. Front. Immunol. 9, 363. doi: 10.3389/
fimmu.2018.00363
Leber, A., Hontecillas, R., Zoccoli-Rodriguez, V., Bienert, C., Chauhan, J., and
Bassaganya-Riera, J. (2019a). Activation of NLRX1 by NX-13 Alleviates
Inflammatory Bowel Disease through Immunometabolic Mechanisms in
CD4(+) T Cells. J. Immunol. 203, 3407–3415. doi: 10.4049/jimmunol.1900364
Leber, A., Hontecillas, R., Zoccoli-Rodriguez, V., Ehrich, M., Chauhan, J., and
Bassaganya-Riera, J. (2019b). Exploratory studies with NX-13: oral toxicity and
pharmacokinetics in rodents of an orally active, gut-restricted first-in-class
therapeutic for IBD that targets NLRX1. Drug Chem. Toxicol., 1–6. doi:
10.1080/01480545.2019.1679828
Lei, Y., Wen, H., Yu, Y., Taxman, D. J., Zhang, L., Widman, D. G., et al. (2012).
The mitochondrial proteins NLRX1 and TUFM form a complex that regulates
type I interferon and autophagy. Immunity 36, 933–946. doi: 10.1016/
j.immuni.2012.03.025
Lei, Y., Kansy, B. A., Li, J., Cong, L., Liu, Y., Trivedi, S., et al. (2016). EGFR-targeted
mAb therapy modulates autophagy in head and neck squamous cell carcinoma
through NLRX1-TUFM protein complex. Oncogene 35, 4698–4707. doi:
10.1038/onc.2016.11
Li, H., Zhang, S., Li, F., and Qin, L. (2016). NLRX1 attenuates apoptosis and
inflammatory responses in myocardial ischemia by inhibiting MAVS-
dependent NLRP3 inflammasome activation. Mol. Immunol. 76, 90–97. doi:
10.1016/j.molimm.2016.06.013
Li, Y., Niu, S., Xi, D., Zhao, S., Sun, J., Jiang, Y., et al. (2019). Differences in
Lipopolysaccharides-Induced Inflammatory Response Between Mouse
Embryonic Fibroblasts and Bone Marrow-Derived Macrophages. J. Interferon.
Cytokine Res. 39, 375–382. doi: 10.1089/jir.2018.0167
Ling, A., Soares, F., Croitoru, D. O., Tattoli, I., Carneiro, L. A., Boniotto, M., et al.
(2012). Post-transcriptional inhibition of luciferase reporter assays by the Nod-
like receptor proteins NLRX1 and NLRC3. J. Biol. Chem. 287, 28705–28716.
doi: 10.1074/jbc.M111.333146
Liu, Y., Tang, N., Cao, K., Wang, S., Tang, S., Su, H., et al. (2018). Negative-
Pressure Wound Therapy Promotes Wound Healing by Enhancing
Angiogenesis Through Suppression of NLRX1 via miR-195 Upregulation.
Int. J. Low Extrem. Wounds 17, 144–150. doi: 10.1177/1534734618794856
Lu, P., Hontecillas, R., Abedi, V., Kale, S., Leber, A., Heltzel, C., et al. (2015).
Modeling-Enabled Characterization of Novel NLRX1 Ligands. PloS One 10,
e0145420. doi: 10.1145/2818302
Luo, X., Donnelly, C. R., Gong, W., Heath, B. R., Hao, Y., Donnelly, L. A., et al.
(2020). HPV16 drives cancer immune escape via NLRX1-mediated
degradation of STING. J. Clin. Invest. 130, 1635–1652. doi: 10.1172/JCI129497Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9Lupfer, C., and Kanneganti, T. D. (2013). The expanding role of NLRs in antiviral
immunity. Immunol. Rev. 255, 13–24. doi: 10.1111/imr.12089
Ma, Z., Hopcraft, S. E., Yang, F., Petrucelli, A., Guo, H., Ting, J. P., et al. (2017).
NLRX1 negatively modulates type I IFN to facilitate KSHV reactivation from
latency. PloS Pathog. 13, e1006350. doi: 10.1371/journal.ppat.1006350
Ma, D., Zhao, Y., She, J., Zhu, Y., Zhao, Y., Liu, L., et al. (2019). NLRX1 alleviates
lipopolysaccharide-induced apoptosis and inflammation in chondrocytes by
suppressing the activation of NF-kappaB signaling. Int. Immunopharmacol. 71,
7–13. doi: 10.1016/j.intimp.2019.03.001
Martinon, F., Burns, K., and Tschopp, J. (2002). The inflammasome: a molecular
platform triggering activation of inflammatory caspases and processing of
proIL-beta. Mol. Cell 10, 417–426. doi: 10.1016/S1097-2765(02)00599-3
Mason, D. R., Beck, P. L., and Muruve, D. A. (2012). Nucleotide-binding
oligomerization domain-like receptors and inflammasomes in the
pathogenesis of non-microbial inflammation and diseases. J. Innate Immun.
4, 16–30. doi: 10.1159/000334247
Moore, C. B., Bergstralh, D. T., Duncan, J. A., Lei, Y., Morrison, T. E.,
Zimmermann, A. G., et al. (2008). NLRX1 is a regulator of mitochondrial
antiviral immunity. Nature 451, 573–577. doi: 10.1038/nature06501
Peng, L., Zhou, Y., Jiang, N., Wang, T., Zhu, J., Chen, Y., et al. (2020). DJ-1 exerts
anti-inflammatory effects and regulates NLRX1-TRAF6 via SHP-1 in stroke.
J. Neuroinflamm. 17, 81. doi: 10.1186/s12974-020-01764-x
Philipson, C. W., Bassaganya-Riera, J., Viladomiu, M., Kronsteiner, B., Abedi, V.,
Hoops, S., et al. (2015). Modeling the Regulatory Mechanisms by Which
NLRX1 Modulates Innate Immune Responses to Helicobacter pylori Infection.
PloS One 10, e0137839. doi: 10.1371/journal.pone.0137839
Qin, Y., Xue, B., Liu, C., Wang, X., Tian, R., Xie, Q., et al. (2017). NLRX1 Mediates
MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate
Immune Response through PCBP2. J. Virol. 91 (23), e01264-17. doi:
10.1128/JVI.01264-17
Rebsamen, M., Vazquez, J., Tardivel, A., Guarda, G., Curran, J., and Tschopp, J.
(2011). NLRX1/NOD5 deficiency does not affect MAVS signalling. Cell Death
Differ. 18, 1387. doi: 10.1038/cdd.2011.64
Shibutani, S. T., Saitoh, T., Nowag, H., Munz, C., and Yoshimori, T. (2015).
Autophagy and autophagy-related proteins in the immune system. Nat.
Immunol. 16, 1014–1024. doi: 10.1038/ni.3273
Singh, K., Poteryakhina, A., Zheltukhin, A., Bhatelia, K., Prajapati, P., Sripada, L.,
et al. (2015). NLRX1 acts as tumor suppressor by regulating TNF-alpha
induced apoptosis and metabolism in cancer cells. Biochim. Biophys. Acta
1853, 1073–1086. doi: 10.1016/j.bbamcr.2015.01.016
Singh, K., Sripada, L., Lipatova, A., Roy, M., Prajapati, P., Gohel, D., et al. (2018).
NLRX1 resides in mitochondrial RNA granules and regulates mitochondrial
RNA processing and bioenergetic adaptation. Biochim. Biophys. Acta Mol. Cell
Res. 1865, 1260–1276. doi: 10.1016/j.bbamcr.2018.06.008
Singh, K., Roy, M., Prajapati, P., Lipatova, A., Sripada, L., Gohel, D., et al. (2019).
NLRX1 regulates TNF-alpha-induced mitochondria-lysosomal crosstalk to
maintain the invasive and metastatic potential of breast cancer cells.
Biochim. Biophys. Acta Mol. Basis Dis. 1865, 1460–1476. doi: 10.1016/
j.bbadis.2019.02.018
Soares, F., Tattoli, I., Wortzman,M. E., Arnoult, D., Philpott, D. J., and Girardin, S. E.
(2013). NLRX1 does not inhibit MAVS-dependent antiviral signalling. Innate
Immun. 19, 438–448. doi: 10.1177/1753425912467383
Soares, F., Tattoli, I., Rahman, M. A., Robertson, S. J., Belcheva, A., Liu, D., et al.
(2014). The mitochondrial protein NLRX1 controls the balance between
extrinsic and intrinsic apoptosis. J. Biol. Chem. 289, 19317–19330. doi:
10.1074/jbc.M114.550111
Stokman, G., Kors, L., Bakker, P. J., Rampanelli, E., Claessen, N., Teske, G. J. D.,
et al. (2017). NLRX1 dampens oxidative stress and apoptosis in tissue injury via
control of mitochondrial activity. J. Exp. Med. 214(8), 2405–2420. doi: 10.1084/
jem.20161031
Tattoli, I., Carneiro, L. A., Jehanno, M., Magalhaes, J. G., Shu, Y., Philpott, D. J.,
et al. (2008). NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-
kappaB and JNK pathways by inducing reactive oxygen species production.
EMBO Rep. 9, 293–300. doi: 10.1038/sj.embor.7401161
Tattoli, I., Killackey, S. A., Foerster, E. G., Molinaro, R., Maisonneuve, C., Rahman,
M. A., et al. (2016). NLRX1 Acts as an Epithelial-Intrinsic Tumor Suppressor
through the Modulation of TNF-Mediated Proliferation. Cell Rep. 14, 2576–
2586. doi: 10.1016/j.celrep.2016.02.065December 2020 | Volume 10 | Article 609812
Snäkä and Fasel NLRX1 in Infection and InflammationTheus, M. H., Brickler, T., Meza, A. L., Coutermarsh-Ott, S., Hazy, A., Gris, D.,
et al. (2017). Loss of NLRX1 Exacerbates Neural Tissue Damage and NF-
kappaB Signaling following Brain Injury. J. Immunol. 199(10), 3547–3558. doi:
10.4049/jimmunol.1700251
Tiku, V., Tan, M. W., and Dikic, I. (2020). Mitochondrial Functions in Infection
and Immunity. Trends Cell Biol. 30, 263–275. doi: 10.1016/j.tcb.2020.01.006
Tong, R., Jia, T., Shi, R., and Yan, F. (2020). Inhibition of microRNA-15 protects H9c2
cells against CVB3-induced myocardial injury by targeting NLRX1 to regulate the
NLRP3 inflammasome.Cell Mol. Biol. Lett. 25, 6. doi: 10.1186/s11658-020-00203-2
Toyama, E. Q., Herzig, S., Courchet, J., Lewis, T. L.Jr., Loson, O. C., Hellberg, K.,
et al. (2016). Metabolism. AMP-activated protein kinase mediates
mitochondrial fission in response to energy stress. Science 351, 275–281. doi:
10.1126/science.aab4138
Unger, B. L., Ganesan, S., Comstock, A. T., Faris, A. N., Hershenson, M. B., and
Sajjan, U. S. (2014). Nod-like receptor X-1 is required for rhinovirus-induced
barrier dysfunction in airway epithelial cells. J. Virol. 88, 3705–3718. doi:
10.1128/JVI.03039-13
West, A. P., Brodsky, I. E., Rahner, C., Woo, D. K., Erdjument-Bromage, H.,
Tempst, P., et al. (2011). TLR signalling augments macrophage bactericidal
activity through mitochondrial ROS. Nature 472, 476–480. doi: 10.1038/
nature09973Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 10Xia, X., Cui, J., Wang, H. Y., Zhu, L., Matsueda, S., Wang, Q., et al. (2011).
NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting
TRAF6 and IKK. Immunity 34, 843–853. doi: 10.1016/j.immuni.2011.02.022
Yin, H., Yang, Q., Cao, Z., Li, H., Yu, Z., Zhang, G., et al. (2018). Activation of
NLRX1-mediated autophagy accelerates the ototoxic potential of cisplatin in
auditory cells. Toxicol. Appl. Pharmacol. 343, 16–28. doi: 10.1016/
j.taap.2018.02.007
Zhang, Y., Yao, Y., Qiu, X., Wang, G., Hu, Z., Chen, S., et al. (2019). Listeria hijacks
host mitophagy through a novel mitophagy receptor to evade killing. Nat.
Immunol. 20, 433–446. doi: 10.1038/s41590-019-0324-2
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Snäkä and Fasel. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.December 2020 | Volume 10 | Article 609812
